[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01GA01, streptomycin, Hydromorphone may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Hydromorphone.]
[A02BX02, sucralfate, Hydromorphone may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Hydromorphone may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The metabolism of Hydromorphone can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Hydromorphone can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The metabolism of Hydromorphone can be decreased when combined with Sulfamethoxazole.]
[J01EC03, sulfamoxole, The metabolism of Hydromorphone can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Hydromorphone can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Hydromorphone can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Hydromorphone can be decreased when combined with Sulfisoxazole.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sulthiame.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Hydromorphone.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L02BA01, tamoxifen, The metabolism of Hydromorphone can be decreased when combined with Tamoxifen.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Temazepam.]
[L01CB02, teniposide, The metabolism of Hydromorphone can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, Hydromorphone may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Hydromorphone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Hydromorphone may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetracaine.]
[S03AA02, tetracycline, Hydromorphone may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Apomorphine.]
[L04AX02, thalidomide, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Hydromorphone may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, The risk or severity of hypotension and CNS depression can be increased when Thiethylperazine is combined with Hydromorphone.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Hydromorphone.]
[N05AB08, thioproperazine, The risk or severity of hypotension and CNS depression can be increased when Thioproperazine is combined with Hydromorphone.]
[N05AC02, thioridazine, The risk or severity of hypotension and CNS depression can be increased when Thioridazine is combined with Hydromorphone.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiothixene.]
[G04BE06, moxisylyte, Hydromorphone may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiapride.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tilidine.]
[S01ED01, timolol, Hydromorphone may decrease the excretion rate of Timolol which could result in a higher serum level.]
[P01AB02, tinidazole, Hydromorphone may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Hydromorphone may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Hydromorphone may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[V04CA01, tolbutamide, Hydromorphone may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the serotonergic activities of Hydromorphone.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Hydromorphone.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Hydromorphone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Triazolam.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Mepenzolate is combined with Hydromorphone.]
[A16AX12, trientine, Hydromorphone may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Hydromorphone.]
[S01AD02, trifluridine, Hydromorphone may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trifluperidol.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Hydromorphone.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hydromorphone.]
[A03AA05, trimebutine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Hydromorphone.]
[R06AD01, trimeprazine, The risk or severity of hypotension and CNS depression can be increased when Alimemazine is combined with Hydromorphone.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trimethadione.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydromorphone.]
[J01EA01, trimethoprim, Hydromorphone may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Triprolidine.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Hydromorphone.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Hydromorphone.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Hydromorphone.]
[R03DX07, roflumilast, Hydromorphone may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Hydromorphone may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Hydromorphone may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[J05AG05, rilpivirine, The metabolism of Hydromorphone can be decreased when combined with Rilpivirine.]
[S01AA28, vancomycin, Hydromorphone may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ezogabine.]
[B01AF01, rivaroxaban, Hydromorphone may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[B01AC24, ticagrelor, Hydromorphone can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08DA01, verapamil, Hydromorphone may decrease the excretion rate of Verapamil which could result in a higher serum level.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Viloxazine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[B01AA03, warfarin, Hydromorphone may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Hydromorphone.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levetiracetam.]
[L01EC01, vemurafenib, The metabolism of Hydromorphone can be decreased when combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[M05BA05, tiludronic acid, Hydromorphone may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Hydromorphone may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[R03DC01, zafirlukast, The metabolism of Hydromorphone can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Hydromorphone may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Hydromorphone may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Hydromorphone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, The risk or severity of adverse effects can be increased when Tolterodine is combined with Hydromorphone.]
[J01DH04, doripenem, Hydromorphone may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[J02AC03, voriconazole, The metabolism of Hydromorphone can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Atracurium is combined with Hydromorphone.]
[S01FA01, atropine, The risk or severity of adverse effects can be increased when Atropine is combined with Hydromorphone.]
[M01CB03, auranofin, Hydromorphone may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Hydromorphone.]
[B03XA04, peginesatide, Hydromorphone may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Hydromorphone may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Hydromorphone may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Hydromorphone may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Hydromorphone may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Hydromorphone.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lorcaserin.]
[G04BD12, mirabegron, Hydromorphone may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[L02BB04, enzalutamide, The serum concentration of Hydromorphone can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Hydromorphone.]
[L01EX05, regorafenib, The metabolism of Hydromorphone can be decreased when combined with Regorafenib.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Hydromorphone.]
[D02BA02, octinoxate, Hydromorphone may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.]
[N04BD02, rasagiline, Rasagiline may increase the serotonergic activities of Hydromorphone.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Hydromorphone.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Thonzylamine is combined with Hydromorphone.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Hydromorphone.]
[V09IX04, fluorodeoxyglucose F18, Hydromorphone may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Hydromorphone.]
[G04BE03, sildenafil, The metabolism of Hydromorphone can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Hydromorphone may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Hydromorphone.]
[A16AX08, teduglutide, Hydromorphone may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Hydromorphone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Hydromorphone may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Hydromorphone.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Benperidol.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[M04AB03, benzbromarone, The metabolism of Hydromorphone can be decreased when combined with Benzbromarone.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Benzocaine.]
[L03AA12, ancestim, Hydromorphone may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Naratriptan.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Benzatropine is combined with Hydromorphone.]
[L01EC02, dabrafenib, The serum concentration of Hydromorphone can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L01EE01, trametinib, Hydromorphone may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Hydromorphone may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Levomilnacipran.]
[A10BJ03, lixisenatide, Hydromorphone may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Hydromorphone may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Eslicarbazepine.]
[J05AP08, sofosbuvir, Hydromorphone may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vigabatrin.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Hydromorphone may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tasimelteon.]
[L04AA32, apremilast, The metabolism of Hydromorphone can be increased when combined with Apremilast.]
[L02BG02, formestane, Hydromorphone may decrease the excretion rate of Formestane which could result in a higher serum level.]
[V03AB34, fomepizole, Hydromorphone may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[L04AC11, siltuximab, The metabolism of Hydromorphone can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Hydromorphone can be decreased when combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hydromorphone.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Hydromorphone.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alfaxalone.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Hydromorphone.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Hydromorphone.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05CM19, suvorexant, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[J01XA05, oritavancin, The metabolism of Hydromorphone can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of hypotension and CNS depression can be increased when Acepromazine is combined with Hydromorphone.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Hydromorphone.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Hydromorphone.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Hydromorphone.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Hydromorphone.]
[S03AA06, gentamicin, Hydromorphone may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AA01, dicumarol, The metabolism of Hydromorphone can be decreased when combined with Dicoumarol.]
[B01AF03, edoxaban, Hydromorphone may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Hydromorphone may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Hydromorphone can be increased when combined with Secukinumab.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Difemerine is combined with Hydromorphone.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Hydromorphone.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Hydromorphone is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Hydromorphone.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cariprazine.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of hypotension and CNS depression can be increased when Acetophenazine is combined with Hydromorphone.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Hydromorphone.]
[V03AB37, idarucizumab, Hydromorphone may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Hydromorphone.]
[J02AC05, isavuconazole, The metabolism of Hydromorphone can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Hydromorphone.]
[L01XG03, ixazomib, Hydromorphone may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Hydromorphone.]
[M04AB05, lesinurad, Hydromorphone may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Hydromorphone.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Hydromorphone may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Brompheniramine is combined with Hydromorphone.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amineptine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Aniracetam.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydromorphone.]
[N07BC01, buprenorphine, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Buspirone.]
[L01XX27, arsenic trioxide, Hydromorphone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Hydromorphone.]
[M02AA03, clofezone, Hydromorphone may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N02AF01, butorphanol, The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Butorphanol.]
[S01GX07, azelastine, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Hydromorphone can be decreased when combined with Rucaparib.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Hydromorphone.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[A06AH05, naldemedine, The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Naldemedine.]
[N07XX16, deutetrabenazine, Hydromorphone may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The therapeutic efficacy of Hydromorphone can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Beclamide.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Hydromorphone may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, Linezolid may increase the serotonergic activities of Hydromorphone.]
[J05AF06, abacavir, Hydromorphone may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[N07XX13, valbenazine, Hydromorphone may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Hydromorphone can be increased when combined with Infliximab.]
[N04BD03, safinamide, Safinamide may increase the serotonergic activities of Hydromorphone.]
[J01MA23, delafloxacin, Hydromorphone may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L01BC06, capecitabine, The metabolism of Hydromorphone can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Hydromorphone can be decreased when combined with Enasidenib.]
[C07AB07, bisoprolol, Hydromorphone may decrease the excretion rate of Bisoprolol which could result in a higher serum level.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Bornaprine is combined with Hydromorphone.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brotizolam.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Hydromorphone may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Hydromorphone.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Butriptyline.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vinylbital.]
[R06AX18, acrivastine, Hydromorphone may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[L02BB05, apalutamide, Hydromorphone may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Hydromorphone may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Hydromorphone.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Camylofin is combined with Hydromorphone.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Carbinoxamine.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Hydromorphone.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Hydromorphone.]
[B02BX08, avatrombopag, The metabolism of Hydromorphone can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, Hydromorphone may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01GB14, plazomicin, Hydromorphone may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[L01XX62, ivosidenib, The metabolism of Hydromorphone can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Hydromorphone may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Hydromorphone.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cetirizine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Carbromal.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Hydromorphone.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Hydromorphone may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydromorphone.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Hydromorphone.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Revefenacin is combined with Hydromorphone.]
[L04AA39, emapalumab, The metabolism of Hydromorphone can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Hydromorphone.]
[B01AC23, cilostazol, Hydromorphone may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Hydromorphone can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Hydromorphone.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Hydromorphone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clobazam.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Hydromorphone.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cloxazolam.]
[C09CA06, candesartan, The metabolism of Hydromorphone can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Hydromorphone can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The serum concentration of Hydromorphone can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Hydromorphone.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Hydromorphone.]
[N07XX11, pitolisant, Hydromorphone may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Hydromorphone.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Yohimbine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Hydromorphone.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Hydromorphone.]
[G03AC09, desogestrel, The metabolism of Hydromorphone can be decreased when combined with Desogestrel.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Hydromorphone.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[M09AX08, golodirsen, Hydromorphone may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexbrompheniramine.]
[S01XA12, dexpanthenol, Hydromorphone may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dezocine.]
[L01EX18, avapritinib, The metabolism of Hydromorphone can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Hydromorphone can be decreased when combined with Diacerein.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Hydromorphone.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Hydromorphone.]
[R02AA03, dichlorobenzyl alcohol, Hydromorphone may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Hydromorphone may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Hydromorphone.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L01XF03, bexarotene, The metabolism of Hydromorphone can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Hydromorphone can be decreased when combined with Clevidipine.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlordiazepoxide.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Dihexyverine is combined with Hydromorphone.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Hydromorphone.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[V08CA05, mangafodipir, Hydromorphone may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dyclonine.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Hydromorphone.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Hydromorphone is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Hydromorphone can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Hydromorphone is combined with Oliceridine.]
[P01BA01, chloroquine, Hydromorphone may decrease the excretion rate of Chloroquine which could result in a higher serum level.]
[L01EX23, pralsetinib, The metabolism of Hydromorphone can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hydromorphone.]
[A10BB02, chlorpropamide, Hydromorphone may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Hydromorphone.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorzoxazone.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etifoxine.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N02BA03, choline salicylate, Hydromorphone may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl loflazepate.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be decreased when combined with Hydromorphone.]
[M01AX25, chondroitin sulfates, Hydromorphone may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01EX21, tepotinib, The metabolism of Hydromorphone can be decreased when combined with Tepotinib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Felbamate.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C01CA19, fenoldopam, Hydromorphone may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[J01DD15, cefdinir, Hydromorphone may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[N02BG07, flupirtine, Hydromorphone may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Hydromorphone.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Hydromorphone can be increased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Hydromorphone can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Gabapentin.]
[V08CA04, gadoteridol, Hydromorphone may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Hydromorphone.]
[S03AA07, ciprofloxacin, Hydromorphone may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01XA01, cisplatin, Hydromorphone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AB03, ioflupane I-123, Hydromorphone may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Hydromorphone may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Hydromorphone may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Hydromorphone.]
[A10BB12, glimepiride, The metabolism of Hydromorphone can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Hydromorphone.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Hydromorphone is combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Hydromorphone can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Hydromorphone.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Hydromorphone.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levobupivacaine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Hydromorphone.]
[C01EB24, mavacamten, The serum concentration of Hydromorphone can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Clozapine is combined with Hydromorphone.]
[J01GB12, arbekacin, Hydromorphone may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Halazepam.]
[S02DA02, cocaine, The risk or severity of adverse effects can be increased when Cocaine is combined with Hydromorphone.]
[C02KB01, metyrosine, Hydromorphone may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Hydromorphone can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Hydromorphone.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Hydromorphone.]
[M04AC01, colchicine, Hydromorphone may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Hexocyclium is combined with Hydromorphone.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Hydromorphone.]
[J01XB01, colistin, Hydromorphone may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AA13, leflunomide, The metabolism of Hydromorphone can be decreased when combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ifenprodil.]
[A10BX03, nateglinide, Hydromorphone may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Hydromorphone.]
[J05AB14, valganciclovir, Hydromorphone may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Hydromorphone may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Hydromorphone may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Hydromorphone may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Hydromorphone may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Hydromorphone may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydromorphone.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Almotriptan.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketazolam.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L01EA01, imatinib, The metabolism of Hydromorphone can be decreased when combined with Imatinib.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Hydromorphone.]
[N03AX09, lamotrigine, The risk or severity of adverse effects can be increased when Lamotrigine is combined with Hydromorphone.]
[N07BC04, lofexidine, The therapeutic efficacy of Hydromorphone can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lormetazepam.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C09AA03, lisinopril, Hydromorphone may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Hydromorphone.]
[C08CA11, manidipine, The metabolism of Hydromorphone can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Mebeverine is combined with Hydromorphone.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Medifoxamine.]
[J01DH02, meropenem, Hydromorphone may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Hydromorphone.]
[R03CB02, methoxyphenamine, Methoxyphenamine may increase the analgesic activities of Hydromorphone.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclobarbital.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Hydromorphone.]
[N06AX07, minaprine, Minaprine may increase the serotonergic activities of Hydromorphone.]
[S01XA18, cyclosporine, Cyclosporine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N06AG02, moclobemide, Moclobemide may increase the serotonergic activities of Hydromorphone.]
[N06BA07, modafinil, The metabolism of Hydromorphone can be decreased when combined with Armodafinil.]
[R06AX02, cyproheptadine, The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Hydromorphone.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Hydromorphone.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH05, etoricoxib, The metabolism of Hydromorphone can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, Hydromorphone may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Hydromorphone can be decreased when combined with Dapsone.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N07BB05, nalmefene, The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Nalmefene.]
[B05XA15, potassium lactate, The therapeutic efficacy of Potassium lactate can be decreased when used in combination with Hydromorphone.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Nordazepam.]
[S01GX04, nedocromil, Hydromorphone may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Niaprazine.]
[C01DX16, nicorandil, Hydromorphone may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, The metabolism of Hydromorphone can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiagabine.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Hydromorphone.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Normethadone.]
[B01AX05, fondaparinux, Hydromorphone may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of adverse effects can be increased when Solifenacin is combined with Hydromorphone.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N06AA01, desipramine, The risk or severity of adverse effects can be increased when Desipramine is combined with Hydromorphone.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Hydromorphone is combined with Desmopressin.]
[V04CH02, indigo carmine, Hydromorphone may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxcarbazepine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxiracetam.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Dexetimide is combined with Hydromorphone.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydromorphone.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Hydromorphone.]
[L04AB04, adalimumab, The metabolism of Hydromorphone can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, Amphetamine may increase the analgesic activities of Hydromorphone.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Hydromorphone.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Paramethadione.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Paroxetine.]
[B01AC04, clopidogrel, Hydromorphone can cause a decrease in the absorption of Clopidogrel resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Diamorphine.]
[P03AC04, permethrin, Hydromorphone may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenacemide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cinchocaine.]
[R05DA08, pholcodine, Hydromorphone may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydromorphone.]
[J05AF02, didanosine, Hydromorphone may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipamperone.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Pipenzolate is combined with Hydromorphone.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, Diethylpropion may increase the analgesic activities of Hydromorphone.]
[L02AA01, diethylstilbestrol, The metabolism of Hydromorphone can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, Isradipine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[D07XC04, diflucortolone, Hydromorphone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Poldine is combined with Hydromorphone.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C01AA05, digoxin, Hydromorphone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Hydromorphone.]
[N07XX04, sodium oxybate, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[S02BA08, fluocinolone acetonide, Hydromorphone may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Hydromorphone may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[L04AX04, lenalidomide, Hydromorphone may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Hydromorphone can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Hydromorphone.]
[H03BC01, potassium perchlorate, Hydromorphone may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Hydromorphone may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Hydromorphone.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Hydromorphone may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pridinol.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Dimetindene is combined with Hydromorphone.]
[M02AX03, dimethyl sulfoxide, Hydromorphone may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Progabide.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C05CA03, diosmin, The metabolism of Hydromorphone can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hydromorphone.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cisapride.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Remoxipride.]
[S01AX06, resorcinol, Hydromorphone may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Hydromorphone.]
[S02AA12, rifamycin SV, The metabolism of Hydromorphone can be decreased when combined with Rifamycin.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydromorphone.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The metabolism of Hydromorphone can be decreased when combined with Bortezomib.]
[G04BE08, tadalafil, Hydromorphone may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C01CA07, dobutamine, Hydromorphone may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[C01CA04, dopamine, Hydromorphone may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of adverse effects can be increased when Dosulepin is combined with Hydromorphone.]
[N06AA12, doxepin, The risk or severity of adverse effects can be increased when Doxepin is combined with Hydromorphone.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Hydromorphone.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.]
[N06AB06, sertraline, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.]
[A08AA10, sibutramine, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Hydromorphone can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Hydromorphone.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Hydromorphone.]
[R03DA01, dyphylline, Hydromorphone may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sumatriptan.]
[V04CX07, edrophonium, Hydromorphone may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[L01AX03, temozolomide, Hydromorphone may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Hydromorphone.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiopropazate.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Hydromorphone.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tianeptine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tofisopam.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N06AG03, toloxatone, Toloxatone may increase the serotonergic activities of Hydromorphone.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Hydromorphone.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Loprazolam.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Triclofos.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Hydromorphone.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trimethobenzamide.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Tropatepine is combined with Hydromorphone.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Hydromorphone.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Veralipride.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Venlafaxine.]
[S01EA01, epinephrine, The metabolism of Hydromorphone can be decreased when combined with Epinephrine.]
[N05CF02, zolpidem, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zotepine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Hydromorphone.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ergotamine.]
[L03AX05, pidotimod, Hydromorphone may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Estazolam.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[G03CA03, estradiol, Hydromorphone may decrease the excretion rate of Estradiol which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J04AK02, ethambutol, Hydromorphone may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[C10AA04, fluvastatin, The metabolism of Hydromorphone can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C01CA15, gepefrine, Gepefrine may increase the analgesic activities of Hydromorphone.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hydromorphone.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Hydromorphone.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Hydromorphone.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethotoin.]
[M01AC06, meloxicam, Meloxicam may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethylmorphine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Hydromorphone.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sertindole.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[R06AX12, terfenadine, The risk or severity of adverse effects can be increased when Terfenadine is combined with Hydromorphone.]
[P01AX07, trimetrexate, Hydromorphone may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Fluvoxamine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Hydromorphone may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Hydromorphone may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Hydromorphone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A16AA01, levocarnitine, Hydromorphone may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[C08CA02, felodipine, The metabolism of Hydromorphone can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Fenfluramine.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fenoterol is combined with Hydromorphone.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fentanyl.]
[R03CC02, albuterol, Hydromorphone may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[L01BB06, clofarabine, Hydromorphone may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Flavoxate is combined with Hydromorphone.]
[C01BC04, flecainide, The metabolism of Hydromorphone can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J02AC01, fluconazole, The metabolism of Hydromorphone can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Hydromorphone may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Hydromorphone may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Melitracen.]
[V03AZ01, ethanol, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The metabolism of Hydromorphone can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Hydromorphone can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Fluoxetine.]
[N05AF01, flupenthixol, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of hypotension and CNS depression can be increased when Fluphenazine is combined with Hydromorphone.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flurazepam.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluspirilene.]
[L02BB01, flutamide, Hydromorphone may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[S02AA17, fosfomycin, Hydromorphone may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L01BC03, tegafur, Hydromorphone may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Alcuronium is combined with Hydromorphone.]
[G01AX06, furazolidone, Furazolidone may increase the serotonergic activities of Hydromorphone.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Hydromorphone is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gallamine is combined with Hydromorphone.]
[S01AD09, ganciclovir, Hydromorphone may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Hydromorphone can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Hydromorphone may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Hydromorphone.]
[J05AG04, etravirine, The metabolism of Hydromorphone can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alfentanil.]
[A06AH02, alvimopan, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alvimopan.]
[A10BB01, glyburide, The metabolism of Hydromorphone can be decreased when combined with Glyburide.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Hydromorphone.]
[A10BB07, glipizide, Hydromorphone may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Glutethimide.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Hydromorphone.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Hydromorphone.]
[L01EX02, sorafenib, The metabolism of Hydromorphone can be decreased when combined with Sorafenib.]
[M01CB04, aurothioglucose, Hydromorphone may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Hydromorphone may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Hydromorphone.]
[C09AA09, fosinopril, Hydromorphone may decrease the excretion rate of Fosinopril which could result in a higher serum level.]
[S01EX01, guanethidine, Hydromorphone may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Hydromorphone.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Halothane.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Quetiapine is combined with Hydromorphone.]
[N06BX13, idebenone, Hydromorphone may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Allobarbital.]
[M04AA01, allopurinol, Hydromorphone may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The metabolism of Losartan can be decreased when combined with Hydromorphone.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Hydromorphone.]
[G03DC01, allylestrenol, Hydromorphone may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Hydromorphone.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Hydromorphone.]
[J05AG01, nevirapine, The metabolism of Hydromorphone can be decreased when combined with Nevirapine.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C09AA04, perindopril, Hydromorphone may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Hydromorphone may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA03, hydrocodone, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Hydromorphone may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Propiverine is combined with Hydromorphone.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Prothipendyl.]
[B05AA07, hetastarch, Hydromorphone may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[B05XA08, sodium acetate, Hydromorphone may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Hydromorphone.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Hydromorphone.]
[L01AA06, ifosfamide, Hydromorphone may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Imipramine is combined with Hydromorphone.]
[R01AD07, tixocortol, Hydromorphone may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tizanidine.]
[L01CE01, topotecan, Hydromorphone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, Indomethacin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[A11HA07, inositol, Hydromorphone may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Milnacipran.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Piperidolate is combined with Hydromorphone.]
[S01XA28, varenicline, Hydromorphone may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Articaine.]
[A10BH01, sitagliptin, Hydromorphone may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alprazolam.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ramelteon.]
[R06AE01, buclizine, The risk or severity of adverse effects can be increased when Buclizine is combined with Hydromorphone.]
[C10AA06, cerivastatin, The metabolism of Hydromorphone can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Hydromorphone may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Iprindole.]
[N06AF05, iproniazid, Iproniazid may increase the serotonergic activities of Hydromorphone.]
[N05AA07, chlorproethazine, The risk or severity of hypotension and CNS depression can be increased when Chlorproethazine is combined with Hydromorphone.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the serotonergic activities of Hydromorphone.]
[P01AX06, atovaquone, The metabolism of Hydromorphone can be decreased when combined with Atovaquone.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Hydromorphone.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Hydromorphone can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Hydromorphone may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[D10BA01, isotretinoin, Hydromorphone may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Hydromorphone.]
[S01AA24, kanamycin, Hydromorphone may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Hydromorphone can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketanserin.]
[B01AC22, prasugrel, Hydromorphone may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Hydromorphone can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Hydromorphone.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[V03AC03, deferasirox, The metabolism of Hydromorphone can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Hydromorphone can be increased when combined with Abatacept.]
[N04BC09, rotigotine, Hydromorphone may increase the sedative activities of Rotigotine.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C07AG01, labetalol, Hydromorphone may decrease the excretion rate of Labetalol which could result in a higher serum level.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Amantadine is combined with Hydromorphone.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Hydromorphone.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Hydromorphone.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lacosamide.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Hydromorphone.]
[S01AA21, amikacin, Hydromorphone may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Hydromorphone can be decreased when combined with Armodafinil.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lorazepam.]
[C10AA02, lovastatin, The metabolism of Hydromorphone can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Loxapine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Hydromorphone.]
[B05XA11, magnesium chloride, Hydromorphone may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Hydromorphone.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Hydromorphone.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Hydromorphone can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Hydromorphone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of adverse effects can be increased when Maprotiline is combined with Hydromorphone.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mazindol.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydromorphone.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Hydromorphone.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Medazepam.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Hydromorphone.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Melatonin.]
[N06DX01, memantine, Hydromorphone may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meperidine.]
[C01CA11, mephentermine, Mephentermine may increase the analgesic activities of Hydromorphone.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mephenytoin.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Hydromorphone.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meprobamate.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meptazinol.]
[G04BX16, tiopronin, Hydromorphone may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of hypotension and CNS depression can be increased when Mesoridazine is combined with Hydromorphone.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Paliperidone.]
[A10BA02, metformin, Hydromorphone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Hydromorphone.]
[N06BA03, methamphetamine, Metamfetamine may increase the analgesic activities of Hydromorphone.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Methantheline is combined with Hydromorphone.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methaqualone.]
[J05AF05, lamivudine, Hydromorphone may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Hydromorphone.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Hydromorphone can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Hydromorphone may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methocarbamol.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methohexital.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ziconotide.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[D05BA02, methoxsalen, Hydromorphone may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Hydromorphone.]
[C02AB01, methyldopa, Hydromorphone may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, Hydromorphone may increase the serotonergic activities of Methylene blue.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Hydromorphone.]
[G03EK01, methyltestosterone, Hydromorphone may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Hydromorphone.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydromorphone.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[P01AB01, metronidazole, The metabolism of Hydromorphone can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, Hydromorphone may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Hydromorphone can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Midazolam.]
[G03XB01, mifepristone, The metabolism of Hydromorphone can be decreased when combined with Mifepristone.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Hydromorphone.]
[J05AH01, zanamivir, Hydromorphone may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The metabolism of Hydromorphone can be decreased when combined with Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may increase the analgesic activities of Hydromorphone.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Molindone.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Hydromorphone can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of adverse effects can be increased when Amitriptyline is combined with Hydromorphone.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Hydromorphone.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Palonosetron.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Hydromorphone can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Hydromorphone can be decreased when combined with Eltrombopag.]
[G04BA01, ammonium chloride, Hydromorphone may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Hydromorphone may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Hydromorphone.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Hydromorphone.]
[P01BA06, amodiaquine, The metabolism of Hydromorphone can be decreased when combined with Amodiaquine.]
[N06AA17, amoxapine, The risk or severity of adverse effects can be increased when Amoxapine is combined with Hydromorphone.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fosphenytoin.]
[C07AA12, nadolol, Hydromorphone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CA04, amoxicillin, Hydromorphone may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N04BC04, ropinirole, Hydromorphone may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Naloxone.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Naltrexone.]
[L04AC03, anakinra, The metabolism of Hydromorphone can be increased when combined with Anakinra.]
[S01GA01, naphazoline, Naphazoline may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.]
[N06BA01, amphetamine, Amphetamine may increase the analgesic activities of Hydromorphone.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[A10BG01, troglitazone, The metabolism of Hydromorphone can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Hydromorphone.]
[S03AA01, neomycin, Hydromorphone may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Remifentanil.]
[B01AC17, tirofiban, Hydromorphone may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[S01AA19, ampicillin, Hydromorphone may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Hydromorphone may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Hydromorphone may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C01CE01, inamrinone, Hydromorphone may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[N06AF02, nialamide, Nialamide may increase the serotonergic activities of Hydromorphone.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Hydromorphone.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Hydromorphone.]
[C08CA05, nifedipine, Hydromorphone may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[C08CA07, nisoldipine, Hydromorphone may decrease the excretion rate of Nisoldipine which could result in a higher serum level.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Nitrazepam.]
[R07AX01, nitric oxide, Hydromorphone may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Hydromorphone may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zaleplon.]
[N04BC05, pramipexole, Hydromorphone may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N01AX13, nitrous oxide, The risk or severity of myocardial depression can be increased when Hydromorphone is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Nomifensine.]
[C02KX01, bosentan, The metabolism of Hydromorphone can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The risk or severity of adverse effects can be increased when Nortriptyline is combined with Hydromorphone.]
[R05DA07, noscapine, The metabolism of Hydromorphone can be decreased when combined with Noscapine.]
[L04AC04, rilonacept, The metabolism of Hydromorphone can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Hydromorphone.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Opium.]
[G04CA02, tamsulosin, Hydromorphone may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[J01CF04, oxacillin, Hydromorphone may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[A14AA08, oxandrolone, The metabolism of Hydromorphone can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxazepam.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Hydromorphone.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Hydromorphone.]
[J04AB30, capreomycin, Hydromorphone may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[N05CC05, paraldehyde, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, Pargyline may increase the serotonergic activities of Hydromorphone.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydromorphone.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Hydromorphone may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Hydromorphone.]
[L01XX08, pentostatin, Hydromorphone may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Hydromorphone may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[N05AB10, perazine, The risk or severity of hypotension and CNS depression can be increased when Perazine is combined with Hydromorphone.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pergolide.]
[N05AB03, perphenazine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Hydromorphone.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Hydromorphone.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the serotonergic activities of Hydromorphone.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Phenobarbital is combined with Hydromorphone.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Hydromorphone.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Hydromorphone.]
[A08AA01, phentermine, Phentermine may increase the analgesic activities of Hydromorphone.]
[V03AB36, phentolamine, Hydromorphone may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The metabolism of Hydromorphone can be decreased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be increased when Phenytoin is combined with Hydromorphone.]
[L04AB06, golimumab, The metabolism of Hydromorphone can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Hydromorphone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Hydromorphone may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pindolol.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N05AC04, pipothiazine, The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Hydromorphone.]
[N06BX03, piracetam, Hydromorphone may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydromorphone.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Piritramide.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Hydromorphone.]
[J05AG02, delavirdine, The metabolism of Hydromorphone can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Hydromorphone.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Proxibarbal.]
[A10BG02, rosiglitazone, Hydromorphone may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hydromorphone.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Hydromorphone can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The metabolism of Hydromorphone can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, Hydromorphone may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Hydromorphone may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Hydromorphone.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Prazepam.]
[H02AB07, prednisone, Hydromorphone may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Prilocaine.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Primidone is combined with Hydromorphone.]
[M04AB01, probenecid, The metabolism of Hydromorphone can be decreased when combined with Probenecid.]
[C01BA02, procainamide, Hydromorphone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, Procaine may increase the serotonergic activities of Hydromorphone.]
[L01XB01, procarbazine, Procarbazine may increase the serotonergic activities of Hydromorphone.]
[C10AB05, fenofibrate, The metabolism of Hydromorphone can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Hydromorphone.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Hydromorphone.]
[G03DA04, progesterone, The metabolism of Hydromorphone can be decreased when combined with Progesterone.]
[N05AA03, promazine, The risk or severity of adverse effects can be increased when Promazine is combined with Hydromorphone.]
[R06AD02, promethazine, The risk or severity of adverse effects can be increased when Promethazine is combined with Hydromorphone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Propanidid.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Hydromorphone.]
[N05AC01, periciazine, The risk or severity of hypotension and CNS depression can be increased when Periciazine is combined with Hydromorphone.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Hydromorphone.]
[N01AX10, propofol, Hydromorphone may increase the sedative activities of Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextropropoxyphene.]
[C07AA05, propranolol, Hydromorphone may decrease the excretion rate of Propranolol which could result in a higher serum level.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Rizatriptan.]
[B01AC09, epoprostenol, Hydromorphone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Hydromorphone.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Protriptyline.]
[R01BA02, pseudoephedrine, Pseudoephedrine may increase the analgesic activities of Hydromorphone.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Aripiprazole is combined with Hydromorphone.]
[N07XX07, dalfampridine, Hydromorphone may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Diphemanil is combined with Hydromorphone.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Isopropamide is combined with Hydromorphone.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Methscopolamine is combined with Hydromorphone.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Hydromorphone.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pyrantel.]
[J04AK01, pyrazinamide, Hydromorphone may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mepyramine.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Hydromorphone.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Quinine.]
[A02BA02, ranitidine, Hydromorphone may decrease the excretion rate of Ranitidine which could result in a higher serum level.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Hydromorphone.]
[J05AP01, ribavirin, Hydromorphone may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxitriptan.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Hydromorphone.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Hydromorphone.]
[N04BD01, selegiline, Selegiline may increase the serotonergic activities of Hydromorphone.]
[J01GB08, sisomicin, Hydromorphone may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Hydromorphone may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Hydromorphone.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloral hydrate.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Hydromorphone.]
[A05AA01, chenodeoxycholic acid, The metabolism of Hydromorphone can be decreased when combined with Chenodeoxycholic acid.]
[C01DA14, isosorbide mononitrate, Hydromorphone may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10AX03, azelaic acid, Hydromorphone may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Hydromorphone.]
